Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health reported Q3 revenue of $1,023.6 million, up 7% year over year, and adjusted EBITDA of $77.2 million, up 13%; adjusted diluted EPS was $0.71. The company narrowed 2026 revenue guidance to $3.9 billion–$4.0 billion and maintained the midpoint of adjusted EBITDA guidance at $261 million–$274 million; it generated $105.4 million of free cash flow through nine months and repaid $115.9 million of debt year to date. Management said Medicaid medical-cost trends are above initial assumptions and anticipates a 10%–15% Medicaid membership decline in 2027; it also described a cybersecurity incident under investigation but provided no quantified impact.

Analysis

ASTH’s better earnings conversion and deleveraging support a constructive view, but the key question is whether new full-risk cohorts can sustain economics as Medicaid membership shrinks and acuity worsens. Full-risk conversion increases earnings upside when care costs beat pricing, but also makes adverse selection and drug-cost surprises hit margins more directly. Texas is an encouraging operating proof point, not yet evidence that every expansion market will replicate it.

The near-term quality check is Q4 and formal 2027 guidance: Q3 included $5–10 million of shared-savings and risk-adjustment sweep benefit that management does not expect to recur in Q4. A sequential EBITDA decline is therefore not, by itself, a deterioration signal. More important are Medicaid medical-cost trends, rates relative to acuity, and whether the forecast mid-teens EBITDA growth survives the expected 10–15% Medicaid membership decline. The new “premiums at risk” measure aids scale comparison but is not GAAP revenue or earnings; avoid treating it as incremental growth.

Care Enablement offers a potentially higher-capital-efficiency growth path and could diversify exposure from premium risk, but two new clients and platform-efficiency claims do not yet establish material external economics. Verify client onboarding, recurring revenue contribution, and implementation costs. The unresolved cyber incident and remediation of a material weakness are separate downside catalysts: either could undermine provider/payer trust or create operational and disclosure costs. ALHC’s mention as a new payer partner is not enough to infer a material earnings impact for ALHC.

Key Decisions for Investors

• ASTH: Favor a staged long rather than chasing the print; add only if Q4 results and formal 2027 guidance support mid-teens EBITDA growth while Medicaid cost trends remain contained. Reassess on any guidance cut, continued deterioration in Medicaid acuity/costs, or a failure of new cohorts to meet underwriting expectations.
• Do not annualize Q3 EBITDA or the $5–10 million sweep benefit. Track recurring operating performance separately from shared-savings/risk-adjustment items; a Q4 step-down consistent with guidance is not thesis-breaking on its own.
• Treat Care Enablement and AI as an option on future operating leverage, not a current earnings driver. Upgrade the thesis only after client onboarding and external revenue/retention evidence; monitor implementation expense and whether G&A leverage continues.
• Keep the cyber incident and material-weakness remediation on the risk dashboard. A disclosed material operational impact, delayed remediation, or evidence of provider/payer disruption would invalidate the constructive setup; no trade in ALHC is warranted from this partner reference alone.